News FAMHP

There are 1 results found(s) based on your search criteria

1-1 from 1 results

Due to a reduction in the manufacturing capacity for the vaccines HAVRIX 1440 and HAVRIX JUNIOR 720 (GSK), used to protect adults and children against hepatitis A, and in order to limit the impact of these supply shortages, alternatives are being proposed The Superior Health Council (SHC) details the correct use of the proposed alternatives in advice number 9260: Recommendation concerning the risk on the shortage supply for hepatitis A vaccine.